These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 1533435

  • 1. Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma.
    Melioli G, Margarino G, Scala M, Mereu P, Bertoglio S, Schenone G, Barbaresi M, Machí AM, Santi L, Badellino F.
    Laryngoscope; 1992 May; 102(5):572-8. PubMed ID: 1533435
    [Abstract] [Full Text] [Related]

  • 2. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL, Letessier E, Hirabayashi H, Vitolo D, Bryant J, Barnes L, Snyderman C, Johnson JT, Myers E, Herberman RB.
    Cancer Res; 1993 Dec 01; 53(23):5654-62. PubMed ID: 8242620
    [Abstract] [Full Text] [Related]

  • 3. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
    Rivoltini L, Gambacorti-Passerini C, Squadrelli-Saraceno M, Grosso MI, Cantù G, Molinari R, Orazi A, Parmiani G.
    Cancer Res; 1990 Sep 01; 50(17):5551-7. PubMed ID: 2386961
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M, Snyderman CH, Heo DS, Johnson JT, d'Amico F, Herberman RB, Whiteside TL.
    Cancer Res; 1990 May 15; 50(10):3113-8. PubMed ID: 2334906
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL, Herberman RB, Olszowy MW, Cramer DV, Salup RR, Reynolds CW, Hiserodt JC.
    Cancer Res; 1988 Feb 15; 48(4):884-90. PubMed ID: 3257412
    [Abstract] [Full Text] [Related]

  • 8. [A phase 2 study of recombinant interleukin 2 (S-6820) for head and neck cancer].
    Sawaki S.
    Gan No Rinsho; 1990 Feb 15; 36(2):111-20. PubMed ID: 2308207
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
    Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW, Chatterjee SK.
    Mol Ther; 2006 Jan 15; 13(1):183-93. PubMed ID: 16125469
    [Abstract] [Full Text] [Related]

  • 11. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
    McMannis JD, Fisher RI, Creekmore SP, Braun DP, Harris JE, Ellis TM.
    J Immunol; 1988 Feb 15; 140(4):1335-40. PubMed ID: 3257776
    [Abstract] [Full Text] [Related]

  • 12. Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.
    Kolitz JE, Welte K, Wong GY, Holloway K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Polivka A, Gabrilove JL.
    J Biol Response Mod; 1987 Aug 15; 6(4):412-29. PubMed ID: 3498011
    [Abstract] [Full Text] [Related]

  • 13. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
    van Herpen CM, van der Laak JA, de Vries IJ, van Krieken JH, de Wilde PC, Balvers MG, Adema GJ, De Mulder PH.
    Clin Cancer Res; 2005 Mar 01; 11(5):1899-909. PubMed ID: 15756016
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.
    Hermann GG, Geertsen PF, von der Maase H, Steven K, Andersen C, Hald T, Zeuthen J.
    Cancer Res; 1992 Feb 01; 52(3):726-33. PubMed ID: 1732060
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells.
    Clayman GL, Taylor DL, Liu FJ, Lavedan P, Savage HE, Schantz SP.
    Laryngoscope; 1993 Mar 01; 103(3):299-307. PubMed ID: 7680086
    [Abstract] [Full Text] [Related]

  • 19. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
    Letessier EM, Heo DS, Okarma T, Johnson JT, Herberman RB, Whiteside TL.
    Cancer Res; 1991 Aug 01; 51(15):3891-9. PubMed ID: 1677310
    [Abstract] [Full Text] [Related]

  • 20. The phenotypic changes in tumour infiltrating lymphocytes and tumour cells following intra-arterial infusion of interleukin-2 in patients with squamous cell carcinoma.
    Salter J, Maclennan KA, Moore J, Dadian G, Riches PG, Gore ME.
    J Pathol; 1995 Jun 01; 176(2):167-73. PubMed ID: 7636627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.